ADA and rheumatoid arthritis: In postmarketing studies of each bDMARD in patients with RA, PCP was complicated in 0.44% of patients for IFX [15], 0.18% for ETN [16], 0.3% for ADA [17], 0.2% for TCZ [18], and 0.1% for ABT [19], respectively.